Wendell David Associates Inc. Purchases 225 Shares of Novo Nordisk A/S (NYSE:NVO)

Wendell David Associates Inc. increased its position in Novo Nordisk A/S (NYSE:NVO) by 0.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,847 shares of the company’s stock after purchasing an additional 225 shares during the period. Wendell David Associates Inc.’s holdings in Novo Nordisk A/S were worth $6,610,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC lifted its holdings in shares of Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC increased its position in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after buying an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in Novo Nordisk A/S during the third quarter valued at $98,765,000. Marshall Wace LLP boosted its holdings in Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after acquiring an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Novo Nordisk A/S in the third quarter worth $42,017,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.5 %

NYSE:NVO opened at $80.59 on Thursday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The business has a fifty day moving average price of $96.63 and a 200-day moving average price of $116.04. The firm has a market capitalization of $361.65 billion, a price-to-earnings ratio of 26.08, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.